Chiome Bioscience Inc.
4583・Growth Market・Pharmaceuticals
Drug Discovery Business
Growth-driving segment responsible for antibody drug discovery and development in areas of high unmet need, and out-licensing of resulting candidates
| Period | Current | Previous | Change |
|---|---|---|---|
| Revenue from external customers (Q1 FY2026 (ending December 2026) cumulative) | ¥0 million | ¥0 million (Q1 FY2025 (ending December 2025) cumulative) | — |
| Segment loss (Q1 FY2026 (ending December 2026) cumulative) | -¥174 million | -¥203 million (Q1 FY2025 (ending December 2025) cumulative) | ↑ |
| Research and development expenses (Q1 FY2026 (ending December 2026) cumulative) | ¥174 million | ¥203 million (Q1 FY2025 (ending December 2025) cumulative) | ↓ |
Business Details
A business model that researches and develops antibody drug candidates targeting disease areas with high unmet need (mainly cancer) using proprietary antibody production technologies (ADLib® System, Tribody®, DoppeLib™), and generates revenue through out-licensing (upfront payments, milestones, royalties) to pharmaceutical companies and others. The segment's primary business domain spans basic/exploratory research through early clinical development stages, with two products, CBA-1205 and CBA-1535, currently in Phase 1 clinical trials. Revenue from external customers is zero, and research and development expenses constitute the entirety of the segment loss.
Recent Overview
Loss narrowed by ¥29 million year-on-year for the standalone Q1 due to decreased clinical development-related expenses
The Drug Discovery Business segment loss for the cumulative first quarter of FY2026 (ending December 2026) was ¥174 million (versus ¥203 million in the same quarter of the prior year). The narrowing of the loss was mainly due to a decrease in recorded clinical development-related expenses compared to the previous period. CBA-1205 continues safety evaluation of the high-dose cohort in the pediatric cancer patient cohort, and CBA-1535 continues safety evaluation of monotherapy dosing. In the IDD Business (Integrated Drug Discovery), joint development of biosimilar cell lines with Alfresa Holdings and Kidswell is proceeding smoothly, and exploration of partnerships with pharmaceutical companies toward creating additional products is also being promoted.
Key Products
Growth Drivers
- Expansion of indications and maximization of product value through continued high-dose safety evaluation of the CBA-1205 pediatric cancer cohort
- Creation of early out-licensing opportunities through accumulation of CBA-1535 monotherapy part data
- Promotion of out-licensing activities for multiple exploratory-stage pipeline candidates including PCDC, PTRY, and PXLR
- Promotion of joint research toward creation of mRNA-encoded antibodies using Tribody®
- Creation of new revenue opportunities such as biosimilar development through the IDD Business (Integrated Drug Discovery)
- Strengthening of multispecific antibody drug discovery capabilities through implementation of DoppeLib™ technology
- Future acquisition of milestone revenue as PFKR's out-licensing partner (Asahi Kasei Therapeutics) advances preclinical trials
Risks
- Risk of clinical trial delays or discontinuation (scientific uncertainty)
- Risk of license agreement termination due to changes in development strategy by out-licensing partner pharmaceutical companies
- Irregularity and one-time nature of out-licensing revenue (dependent on milestones and upfront payments)
- Ongoing operating cash outflow due to upfront research and development investment
- Risk of competitors advancing development of similar targets/modalities ahead of the company
- Risk of delayed commercialization if clinical trial results are insufficient to meet out-licensing conditions
- Non-disclosure of Drug Discovery Business performance forecasts due to difficulty in reasonable estimation, making it difficult for investors to formulate earnings outlooks
Last updated: March 27, 2026